Some of the drug's trial results were about on par with weight loss from gastric bypass surgery.
Molly Liebergall is a Reporter at Daily Newsletter. She covers a diverse range of topics including artificial intelligence, competitive sports, and the beauty and fashion industries, often exploring the intersection of these themes with consumer events and entertainment news. Molly's work has been featured in prominent publications such as Fortune, Billboard, CFP Board, and Morning Brew.
















